



Apotekarsocieteten

17th Symposium on Pharmacokinetics and Drug Metabolism

12-13 November 2024



Preliminary program

Tuesday 12 th November	
11.30 – 13.00	Registration and Lunch
13.00 – 13.15	Opening and introduction of meeting
13.15 – 14.45	Session 1: Biotransformation and impact of drug metabolites Chairs: Johanna Haglund, MetaSafe, Johan Bylund, CTC, Clinical Trial Consultants Speakers: <ul style="list-style-type: none">• "Unusual" Biotransformation Reactions of Drugs and Drug Candidates, Emre Isin, Servier• Drug metabolism in drug discovery-PK, PD and safety aspects, Carl Petersson, Merck Healthcare• Structural elucidation of conjugation drug metabolites by utilizing novel electron-activated dissociation (EAD), Ferran Sánchez, SCIEX
14.45 – 15.30	Break with posters & coffee
15.30 – 17.00	Session 2: Drug Transporter considerations across drug modalities Chairs: Anna Nordmark, Nordmark ClinPharm consulting, Rasmus Jansson-Löfmark, AstraZeneca Speakers: <ul style="list-style-type: none">• Drug transporters and large molecules, Pär Matsson, Gothenburg University• Antibody brain exposure and distribution using a passive or an active transport mechanism in the mission to target brain diseases, Sofia Gustafsson, BioArctic• Translational aspects of oxycodone brain delivery via the proton-coupled organic cation (H⁺/OC) antiporter system: the journey from cells to pigs. Irena Loryan, Translational Pharmacokinetics/Pharmacodynamics group, Dep of Pharmacy Uppsala University• Use of endogenous biomarkers for transporter DDI risk assessments and delineation of complex DDI mechanisms – Case studies from AstraZeneca, Vijender Panduga, AstraZeneca
17.00 – 17.15	Break
17.15 – 18.00	Candlelight lecture Speaker: Bengt Dahlström, PhD, Associate Professor Bengt Dahlström is Associate Professor in Pharmacokinetics and Drug Therapy from Uppsala University, Sweden and has published over 50 scientific papers in this area. He is an expert in pharmacokinetics, drug research and development with over 40 years' experience from leading positions in Pharmaceutical companies and CROs. He is co-founder of leading Clinical Research Organizations: CTC AB, PMC AB, MiniDoc AB and AB Biopharmacon.
18.00 – 18.45	Break & refreshments and poster session
19.00 – 23.00	Dinner

Wednesday 13th November

08.30 – 10.15	<p>Session 3: Pharmacokinetic and pharmacodynamic considerations in rare disease and special populations</p> <p>Chairs: Anna Nordmark, Nordmark ClinPharm Consulting, Mia Lundblad, Novo Nordisk, Pawel Baranczewski SciLifeLab, Uppsala University</p> <p>Speakers:</p> <ul style="list-style-type: none">• Physiologically based pharmacokinetic modelling and simulation in perinatal populations: opportunities, challenges and case examples, Pieter Annaert, Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium• PBPK simulations in special populations. Are we ready for prime time? Eva Berglund, Certara Drug Development Services, Certara• Clinical Pharmacology considerations for development of Sogroya (somapacitan) for rare pediatric growth disorders, Rasmus Juul Kildemoes, Clinical Pharmacology RD&AT, Novo Nordisk• Model-informed development of Mim8 – a novel bispecific antibody for the treatment of haemophilia A, Mads Kreilgaard, Pharmacometrics, Novo Nordisk
10.15 – 10.45	Break with posters & coffee
10.45 – 12.15	<p>Session 4: Bridging strategies for drug-device products</p> <p>Chairs: Markus Fridén, AstraZeneca, Mia Lundblad, Novo Nordisk</p> <p>Speakers:</p> <ul style="list-style-type: none">• Ambition Zero Carbon: Accelerating adoption of Next Generation Propellant inhalation sprays by linking propellant and aerosol physics to predicted lung efficacy, Duy Nguyen & Michael Williams, AstraZeneca• Improved bioequivalence assessment through model-informed and model-based strategies, Andy Hooker, Uppsala University• Biopharmaceutical Evaluation of the Subcutaneous Administration, Marta Vencel, Sanofi
12.15 – 13.15	Lunch
13.15 – 13.45	Rosenön Award
13.45 – 14.45	<p>Session 5: Pharmacokinetics-Pharmacodynamics of drug combination therapies</p> <p>Chairs: Markus Fridén, AstraZeneca, Rasmus Jansson-Löfmark, AstraZeneca</p> <p>Speakers:</p> <ul style="list-style-type: none">• Development of a pre-clinical model-based drug regimen platform for antibiotics within a European perspective, Ulrika Simonsson, Uppsala University• Speaker – to be confirmed
14.45 – 15.00	Closure of meeting